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Abstract  
Colloidal gold solutions have been used for centuries in a wide variety of applications 
including staining glass and in the colouring of ceramics. More recently, gold nanoparticles 
(GNPs) have been studied extensively due to their interesting size-dependent electronic and 
optical properties. GNPs can be functionalized easily with biomolecules that contain thiols, 
amines, or even phosphine moieties. For example, the reaction of thiol-containing peptides 
with GNPs has been used extensively to prepare novel hybrid materials for biomedical 
applications. A range of different types of peptides can be used to access biomaterials that are 
designed to perform a specific role such as cancer cell targeting. In addition, specific peptide 
sequences that are responsive to external stimuli (e.g. temperature or pH) can be used to 
stabilise / destabilise the aggregation of colloidal GNPs. Such systems have exciting potential 
applications in the field of colorimetric sensing (including bio-sensing) and in targeted drug 
delivery platforms.  In this review, we will give an overview of the current methods used for 
preparing peptide functionalized GNPs, and we will discuss their key properties outlining the 
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various applications of this class of biomaterial. In particular, the potential applications of 
peptide functionalized GNPs in areas of sensing and targeted drug delivery will be discussed.   
 
1. Introduction 
Colloidal gold solutions have been known and used, since ancient times, for staining glass 
and colouring ceramics. In more recent times, gold nanoparticles (GNPs) have been 
extensively studied due to their size dependent electronic and optical properties.1, 2 In the 
early 1950s, Turkevich developed an approach for the synthesis of GNPs3, which involved 
the reduction of hydrogen tetrachloroaurate (III) (HAuCl4) in water by a reducing 
agent/stabilising ligand, such as sodium citrate. Using this process, GNPs with a size ca. 
20nm can be prepared. Later, Frens improved this method and obtained GNPs with a more 
controlled diameter (between 16 and 147 nm).4 In this later approach, the trisodium citrate to 
gold ratio controls the size of the GNPs: a higher ratio gives a smaller particle size. GNPs can 
be easily functionalized with biomolecules which contain thiols, amines, or even phosphine 
moieties. The most common approach is to functionalize GNPs with thiol containing 
molecules. Using this method it has been possible to synthesize novel hybrid materials 
consisting of combinations of GNPs and proteins (or peptides). The peptides and proteins 
utilised in these systems can fulfil different roles, acting as drug carriers, anti-cancer drugs 
and even cellular targeting moieties.5, 6 
In the last decade, a variety of peptide functionalized GNPs have been synthesized and 
applied in a range of areas including bio-detection, targeted drug delivery and cellular uptake 
studies.7-10 Adding peptides to citrate-capped GNPs can produce highly stable peptide-capped 
nanoparticles even in an aqueous buffer. The ability to assemble/disassemble GNPs can be 
modulated by changing the peptide sequence. For example, pH-responsive peptides can alter 
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their conformation in response to changes in their local environment and this can lead to 
aggregation of GNPs which will itself give rise to a visual colour change.11  
In this review, the discussion will focus primarily on the different methods of preparing 
peptide functionalized GNPs, their properties and their use in various biomaterials 
applications. In particular, applications in the areas of metal ion and molecular detection and 
targeting drug delivery will be discussed in more detail.  
 
2. Synthesis of Peptide-functionalized Gold Nanoparticles (GNPs) 
Generally, a colloidal gold solution is produced by the reduction of chloroauric acid 
(HAuCl4). The Frens method is the simplest approach to produce citrate-capped nanoparticles 
of controlled diameter4. The resulting citrate-GNPs have been further functionalized with 
different peptides to improve their stability. There are three main approaches of preparing 
peptide-functionalized GNPs: (1) ligand exchange; (2) chemical reduction; and (3) chemical 
conjugation. 
 
2.1 Ligand Exchange 
The ligand exchange method is the most commonly used approach to prepare peptide-GNPs. 
It essentially involves displacement of one ligand for another,12, 13 and was first explored by 
Hostetler et al.12 who attempted to replace simple thiol ligands on GNPs with more complex 
thiols. The ligand exchange method has been used successfully to synthesise a range of GNPs 
capped with cysteine-containing peptides. Tetrachloroaurate ions (AuCl4
-) are firstly reduced 
by sodium citrate and citric acid to give citrate-stabilized GNPs. In the presence of Cys-
capped peptides the citrate-stabilized GNPs undergo ligand exchange to give peptide 
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functionalized GNPs.14, 15 This reaction proceeds as the cysteine containing peptides have a 
stronger interaction with the GNPs compared to the citrate ions. The sulfur-gold bond has a 
strength of approximately 210 kJ mol-1.16 This ligand exchange method is very useful when 
the desired thiol ligand is valuable or not compatible with the reductive environment. A 
single thiol group can already be quite strong as a binding ligand to a gold surface, however, 
in some complex systems, multiple thiols may be desired if higher chemical stability is 
required. For example, Lin et al.17 reported a two-step method to attach neutral and positively 
charged thiols onto the gold surface (Figure 1). The first step is to reduce tetrachloroauric 
acid with sodium citrate and then replace the citrate with thioctic acid (TA). In the second 
step, TA is replaced by functional groups containing thiols. Through the two-step approach, 
stable gold nanoparticles can be functionalized with a wide range of thiols including those 
bearing positive charges.  
 
Figure 1. A two-step modification method for functionalising gold nanoparticles.17 Reprinted 
with permission from S.-Y. Lin, Y.-T. Tsai, C.-C. Chen, C.-M. Lin and C.-H. Chen, J. Phys. 
Chem. B, 2004, 108, 2134-2139. Copyright 2004 American Chemical Society. 
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2.2 Chemical Reduction   
In 2005, Bhattacharjee et al.18 reported an approach to prepare colloidal GNP-tripeptides 
through an in situ tyrosine reduction technique. The designed tripeptide sequence was H2N-
Leu-Aib-Tyr-OMe (Aib is 2-aminoisobutyric acid, or 2-methylalanine); tyrosine was 
included at the C-terminus to act as an electron-transfer agent.19 The tyrosine reduces AuCl4
- 
to Au0, and the free amine at the N-terminus of the tripeptide can attach to the gold surface 
resulting in a colloidal suspension. The size of the tripeptide-GNPs prepared via this 
approach was relatively small, around 8.7 nm. However, when excess tri-peptides were added 
to a gold salt solution, the resultant tripeptide-GNPs aggregated due to H-bonding between 
the terminal NH2 group and side chains of amino acid residues. Other tyrosine containing 
peptides have also been used to synthesise peptide-GNPs. For example, the peptide 
NPSSLFRYLPSD was used to reduce gold ions to GNPs and subsequently form organic-
inorganic hybrid nanoparticles.20 Higher temperatures decreased the size of the nanoparticles 
that were obtained.  
In 2009 Serizawa et al.21 reported another method for the synthesis of peptide functionalised 
GNPs by reduction using HEPES buffer. The reduction was carried out in the presence of 
Cys-terminal basic peptides under ambient conditions. This approach solved the difficulties 
typically associated with the functionalization of GNPs with peptides containing basic amino 
acids, such as Arg-Pro-Thr-Arg (RPTR), which tends to result in GNP aggregation and 
precipitation. 
 
2.3 Chemical Conjugation 
Generally, GNPs are formed in aqueous solution and capped by water-soluble stabilizers, 
such as thiolated derivatives of PEG, glutathione or mercaptosuccinic acid. These stabilizers 
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often have active sites that can be used to bind peptides and other biomolecules. This method 
of combining peptides to GNPs is known as the chemical conjugation method.  
In 2009, Xie et al.22 showed that nuclear localization signal (NLS) peptide functionalized-
GNPs can be used as a nuclear targeting nanoprobe. The nanoparticles were first modified by 
11-mercaptoundecanoic acid (11-MUA), and the NLS peptide was then connected to the 
modified GNPs by carbodiimide coupling (Figure 2). Bartczak and co-workers23 developed a 
one-pot synthesis method using EDC/sulfo-NHS (N-hydroxy sulfosuccinimide) coupling to 
conjugate the peptide KPQPRPLS to carboxy-terminated oligoethyleneglycol gold 
nanoparticles (OEG NPs). The degree of peptide coupling was affected by experimental 
parameters, such as reaction time, concentration of reagent and the morphology of the 
nanocrystal.  
 
Figure 2. Preparation of nuclear localising signal peptide-functionalised gold nanoparticles.22 
Reprinted with permission from W. Xie, L. Wang, Y. Zhang, L. Su, A. Shen, J. Tan and J. Hu, 
Bioconjug. Chem., 2009, 20, 768-773. Copyright 2009 American Chemical Society. 
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3. Properties of Peptide-Functionalized Gold Nanoparticles 
3.1 pH Responsiveness 
The first detailed study of reversible self-assembly of peptide-capped GNPs at different pH 
values was reported by Mandal et al. in 2007.11 The tyrosine reduction technique18 was used 
to obtain GNPs functionalised with H2N-Leu-Aib-Tyr-OMe. UV-vis spectroscopy showed 
that when the pH decreased, the surface plasmon resonance (SPR) band displayed a red shift 
along with a visual colour change of the peptide-GNP from red to violet. This indicates GNP 
assembly due to H-bonding between –COOH groups on the gold surface when the solution 
pH is near the pKa of the carboxylic acid. TEM results showed that the peptide-GNPs formed 
a network of 1D chains at pH 4; when the pH decreased below 4, assemblies of 2D 
nanostructures and, finally, 3D structures, were observed as shown in Figure 3. When the pH 
was increased to 7, the peptide-GNPs disassembled again, demonstrating reversibility. The 
process is driven only by peptide H-bonding interactions, as evidenced by the fact that when 
the same UV-vis experiments were carried out using un-functionalized GNPs, no assembly 
occurred. This work demonstrates that carboxylated peptide-functionalized GNPs can be 
affected by pH to give assembly/disassembly driven by H-bonding interactions.  
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Figure 3. Self-assembly and disassembly of pH-responsive peptide-GNPs.11 Reprinted with 
permission from S. Si and T. K. Mandal, Langmuir, 2007, 23, 190-195. Copyright 2007 
American Chemical Society.  
 
In 2010, van Hest et al.24 reported the preparation of elastin-like peptide (ELP) functionalised 
GNPs, which are temperature and pH responsive. In their system, the short ELP VPGVG was 
used to functionalise GNPs through a ligand-exchange reaction. VPGVG undergoes a 
structural transition from a hydrophilic random coil to a hydrophobic β-spiral when the 
temperature is increased. The same behaviour was expected of the VPGVG-GNPs, however 
the VPGVG-GNPs solutions showed no LCST until the pH value dropped below pH 3.3. 
UV-visible spectroscopy demonstrated that the transition temperature is pH dependent, and 
the LCST varies from 14 to 41oC when the pH changes from 2.1 to 3.3. This is due to the fact 
that the VPGVG peptide has a free carboxylic acid at the C-terminus, which is protonated at 
low pH leading to a more hydrophobic VPGVG peptide. The VPGVG-GNPs displays the 
same LCST behaviour, which can be modulated by altering pH.  
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Minelli et al.25 designed stimuli responsive 1.4 nm GNPs functionalised with a pH sensitive 
coiled coil peptide (pHcc) to obtain a reversible system sensitive to environmental pH. The 
peptide sequence was Ac-CGGGE-Helix-CONH2, where the helix sequences is VSALENE-
VAKLKNE-VKYLEAE-VARLKNE-VEFLEK. The pHcc peptide undergoes a reversible 
conformational change from a α-helix to random coil when the pH is increased from 2 to 7. 
Due to this behaviour, the pHcc can bind to a GNP surface via coiled coil assembly at pH 4, 
however at pH 7 the binding does not occur because the conformation changes to a random 
coil. This strategy can be applied to reversible molecular binding by pH control. 
 
3.2 Enhanced stability for use in biological environments  
In 2004 Levy et al.14 developed Cys-Ala-Leu-Asn-Asn (CALNN) stabilized GNPs. This 
peptide gives extremely stable, water-soluble GNPs which can be further functionalized with 
biomolecules. The cysteine (C) at the N-terminus is able to form a linkage to the gold surface, 
while the interior hydrophobic amino acids alanine (A) and leucine (L) promote peptide self-
assembly. The hydrophilic asparagine (N) which has a negative charge at the C-terminus is 
exposed to the external aqueous solution. This designed pentapeptide-functionalized GNP is 
stable at different pH values and in various buffer ionic strengths. More importantly, 
CALNN-GNPs remain stable even when decorated with longer peptides or proteins which 
opens up options to develop biological applications for this system.  Subsequently, Wang et 
al.26 prepared CALNN-GNPs functionalised with both DNA and biotin in a single easy step 
preparation. These particles exhibit specific binding ability to DNA and protein microarrays 
via their biological functionalities. This approach could be applied to a variety of peptide 
recognition motifs with high specificity and affinity. 
10 
 
Krpetic and coworkers 15 designed a peptide with four cysteine moieties to produce GNPs of 
enhanced stability. The peptide, named GCK15, has the sequence GCGGCGGKGGCGGCG; 
TEM, UV-Vis and FT-IR data showed that uniform GCK15-GNPs formed with no 
aggregation. In this system, the GCK15 ‘multi-dentate’ peptide not only provides stable gold 
nanoparticles, but also has a single lysine residue which can be further functionalized.  
‘Stealth’ peptide-capped GNPs which do not aggregate even in high salt solutions or in 
human serum were reported in 2014 by Nowinski et al.27 The repeated glutamic acid (E) and 
lysine (K) amino acids in the peptide EKEKEK create a hydration layer that resists protein 
adsorption. Viability assays with endothelial cells and macrophages showed that EKEKEK-
GNPs are not toxic in all test concentrations and resist internalisation. However, when a 
cyclic RGD was combined with the EKEKEK peptide, the cRGD-EK-GNPs were taken up 
efficiently. Therefore, the peptide-coated GNPs provide a very stable and stealthy 
nanoparticle system, which could possibly achieve long blood circulation half-life. Also, their 
stealth property can be altered by adding specific cell uptake motifs. 
 
3.3 Self-assembly 
Increasingly, studies are focusing on designed self-assembling structures and hybrid 
nanomaterials, aiming at building synthetic polypeptides with the same chemical flexibility as 
proteins but which have sensitivity to environmental changes and which can reversibly 
change their conformation.  There are two methods commonly used to control peptide-GNP 
self-assembly: protease action or metal-ion complexation. 
In 2007, Laromaine et al.28 reported a short peptide-functionalized GNP system in which the 
assembly was controlled by the protease thermolysin, which catalyses the hydrolysis of 
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peptides containing hydrophobic amino acids. The tri-peptide sequence Fmoc-Gly-Phe-Cys-
NH2 was attached to the gold surface, and underwent self-assembly because of the Fmoc 
groups’ ᴨ-stacking ability. When thermolysin was added into the solution, the amide bond 
between Gly and Phe was hydrolysed and disassembly occurred immediately, producing a 
clear colour change (Figure 4). This simple and very sensitive method offered a means by 
which to develop colorimetric assays to detect the presence of proteases.  
 
Figure 4. (A) GNP dispersion upon inclubation with a protease; (B) TEM image showing 
GNPs functionalized with Fmoc-Gly-Phe-Cys-NH2; (C) TEM image of system in (B) 
following addition of thermolysin.28 Reprinted with permission from A. Laromaine, L. Koh, 
M. Murugesan, R. V. Ulijn and M. M. Stevens, J. Am. Chem. Soc., 2007, 129, 4156-4157. 
Copyright 2007 American Chemical Society. 
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Aili et al.29 studied the reversible assembly of polypeptide-coated GNPs by adding a 
polypeptide linker which can associate with immobilized surface peptides in a folding-
dependent manner. JR2EC, a glutamic acid-rich, 42 residue peptide 
(NAADLEKAIEALEKHLEAKGPCDAAQLEKQLEQAFEAFERAG), was used to 
functionalise gold nanoparticles. It has a random coil structure at pH 7 but can change into a 
four-helix bundle structure when the pH is lower than 6, or in the presence of Zn2+.30 The 
JR2EC-functionalized GNPs dispersed in EDTA containing buffer were stable, while 
aggregation was observed when polypeptide JR2KC2 
(NAADLKKAIKALKKHLKAKGPCDAAQLKKQLKQAFKAFKRAG) was added.  The 
JR2KC2 peptide associates with helix-loop-helix peptide JR2EC and folds into two 
disulphide-linked four-helix bundles. The disulphide bridge can be removed by adding tris(2-
carboxyethyl)phosphine (TCEP), resulting in slow redispersion of the aggregated GNPs. In 
this study, the optical property of GNPs was an important tool to demonstrate the molecular 
interaction.  
Subsequently, a novel method of colorimetric protein assay based on the concept of 
reversible assembly of polypeptide-coated GNPs was developed.31 The recognition is 
designed using a peptide sensor which can bind to the enzyme human carbonic anhydrase II 
(HCAII). In the absence of HCAII, the GNPs aggregate strongly which gives a large red shift 
of the plasmon peak. When there is HCAII, the immobilized peptides on the gold surface 
bind to the enzyme and prevent the GNPs from aggregating, leading to no colour change. 
This is because the steric hindrance by the bound enzyme prevents the folding of the 
immobilized polypeptides. The clear colour shift provides a very simple sensor which can be 
detected by the naked eye. They also proved that this detection system can be used to 
recognize a peptide sequence (C-pTMVP) form an antibody fragment (Fab57P). The 
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polypeptide-coated gold nanoparticles are very stable over a long time period and hence they 
have the potential to be applied in colourimetric sensing.   
The self-assembly of peptide-functionalized GNPs induced by chelation of carboxylate 
groups by metal ions, such as Pb2+, Cd2+, Cu2+ or Zn2+, has been investigated.32 GNPs were 
formed by in situ reduction by tyrosine and the tripeptide H2N-Leu-Aib-Tyr-OMe was 
attached to the GNP surface. In the presence of sodium hydroxide, the peptides were 
hydrolysed to sodium carboxylate. When heavy metal ions were added to the peptide-GNPs, 
self-assembly occurred instantly and gave a colour change from red to blue, due to the 
formation of a chelate complex. The whole process takes ca. 15 min to complete (Figure 5) 
and be reversed by adding concentrated alkaline EDTA solution. The study showed that this 
self-assembly was only driven by chelation, and not affected by pH or salt concentration.  
 
Figure 5. Reversible self-assembly of carboxylated peptide-GNPs in the presence of metal 
ions.32 Reproduced with permission © Wiley-VCH, 2008. 
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4. Applications of Peptide-Functionalized Gold Nanoparticles 
4.1 Detection 
Peptide-functionalized GNPs have unique optical and electronic properties and their 
assembly can be triggered by changes in their local environment. Increasingly, studies have 
been performed to apply these properties in the biomedical area, such as in the detection of 
metal ions, enzymes and antibodies. 
In the detection of heavy metal ions, several studies have appeared in the literature since 2007. 
Si et al.33 developed the first peptide-functionalized GNPs to detect Hg2+ ions in solution. In 
this work, peptide-GNPs stabilised by H2N-Leu-Aib-Tyr-OMe were prepared. The UV-Vis 
spectrum of the peptide-GNPs solution showed an absorbance peak at 527 nm, but after 
adding Hg2+ ions, another peak at wavelength ca. 670 nm was observed. This was 
accompanied by a solution colour change from red to purple (Figure 6). When alkaline 
EDTA solution was added, the purple colour turned back to red. This method can detect Hg2+ 
ions in solution at concentrations above 4 ppm, either by the naked eye or by UV-vis 
spectroscopy.  
 
Figure 6. Detection of Hg2+ ions using a peptide-GNP solution.33 Reprinted with permission 
from S. Si, A. Kotal and T. K. Mandal, J. Phys. Chem. C, 2007, 111, 1248-1255. Copyright 
2007 American Chemical Society. 
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Slocik and co-workers34 demonstrated another peptide-functionalized gold nanoparticle (PFN) 
system as a colorimetric sensor for various metal ions (Co2+,  Hg2+, Pb2+, Pd2+ and Pt2+). In a 
one-pot process in HEPES buffer, the peptide DYKDDDDKPAYSSGPAPPMPPF reduced 
AuCl4
- and coated the surface of the resulting GNPs producing stable and multifunctional 
GNPs in solution. When the PFNs complexed with different metal ions, a reproducible and 
specific surface plasmon resonance (SPR) trace as well as a colourimetric response was 
shown for each metal ion (Figure 7).  
 
Figure 7. Response of peptide-functionalised gold nanoparticles (PFNs) to various metal ions. 
(A) photographs of PFN solutions after additon of various metal salts; (B) UV/Vis spectra 
corresponding to the photographs in (A).34 Reproduced with permission © Wiley-VCH, 2008. 
 
Wang et al.35 studied β-amyloid peptide (Aβ1-16)-functionalized GNPs as a colourimetric 
indicator for Zn2+. The peptide Aβ1-16 (DAEFRHDSGYEVHHQK) was linked to the gold 
surface through biotin-streptavidin chemistry. β-Amyloid peptide aggregation in the presence 
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of Zn2+ was confirmed by UV-vis spectroscopy and TEM. This aggregation precess can be 
reversed when EDTA is added to the solution. The mechasim of this colourimetric detector is 
based on the chelation between the β-amyloid peptide and the metal ion Zn2+. Later in 2012, 
Wang et al.36 discussed another colourimetric assay for detecting Pb2+ in presence of living 
cells based on CALNN and glutathione (Glu-Cys-Gly) functionalized GNPs. CALNN was 
used as a stablizer for the GNPs under physiological conditions, while glutathione was used 
as the sensor element as it can react with Pb2+. In both aqueous solution and in the presence 
of HeLa cells, metal ions including Zn2+, Cu2+, Fe2+, Hg2+ and Pb2+ were added separately to 
GNP solutions. The results indicated that the CALNN and GSH bifunctionalized GNPs have 
a high selectivly for Pb2+. In the living cell experiment, the colourimetric assay could detect 
down to 2.9 fmol of Pb2+ per cell.  
A peptide-functionalized GNP as a sensing probe for detecting in parallel mixed metal ions, 
such as Cd2+, Ni2+ and Co2+, has been developed.37 CALNNDHHHHHH contains a biostable 
sequence as well as a metal ion sensing sequence (histidine (H) is known to bind certain 
metal ions via the imidazole ring). The designed peptide-functionalized GNPs were highly 
dispersed in buffer solution, however they were found to aggregate in the presence of Cd2+, 
Ni2+ and Co2+. The colour of the peptide-GNP probe gradually changed from red to purple or 
blue. A linear relationship between the concentration of each metal ion and the ratio of 
absorbance at wavelengths 600 nm and 520 nm (A600/A520) was found. The colourimetric 
response of Cd2+ was more obvious than Ni2+ and Co2+ and the detection limit was as low as 
0.05 µM. The method is simple, quick and accurate for real samples which contain mixtures 
of various metal ions.  
Many enzymes hydrolyse peptide bonds and thus can be used as a starting point to design a 
detection method for targeted enzymes. In 2008, Zhen et al.38 reported a simple peptide-GNP 
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system to detect thrombin proteolytic activity. The peptide attached to the GNPs has the 
sequence GLACSGFPRGRW; and in the presence of thrombin, a serine protease, the R-G 
amide bond is cleaved. After centrifugation, strong fluorescence was found in the supernatant 
because of the tryptophan residue. As shown in Figure 8, the success of the cleavage can be 
confirmed by strong fluorescence of the GRW fragment. From the experimental data, a linear 
relationship between the concentration of thrombin and fluorescence intensity was found. 
This method can easily be applied to real blood samples to detect thrombin in one hour.  
 
Figure 8. A peptide-GNP-based thrombin assay. The peptide covalently bound to the GNPs 
is cleaved at a specific site by thrombin. The GRW fragment so produced migrates to the 
supernatant and can be detected.38 Reproduced with permission © Elsevier, 2008. 
 
A colourimetric detection of the matrix metalloproteinase matrilysin (MMP-7) based on 
JR2EC-functionalized GNPs has been described.39 GNPs were modified through the cysteine 
in the middle of the JR2EC sequence 
(NAADLEKAIEALEKHLEAKGPCDAAQLEKQLEQAFEAFERAG), via a thiol-gold 
linkage. MMP-7 can recognize and cleave two sites in JR2EC, Ala-Leu and Gln-Leu, 
resulting in a reduction in peptide size and overall net charge.  The GNPs responded to this 
cleavage by aggregation, a localized surface plasmon resonance (LSPR) shift and a colour 
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change from red to blue. Control experiments were undertaken to verify the aggregation of 
GNPs was only because of the digestion of JR2EC by MMP-7, not because of chelation in 
the presence of metal ions Zn2+ and Ca2+. As the level of MMP-7 in the salivary gland of 
cancer patients is higher (ca. >5 nM) than in healthy patients and the assay has a detection 
limit as low as 5nM, it shows promise as a diagnostic tool for salivary gland cancer. The 
JR2EC peptide was further used to probe Zn2+-protein-chelant interactions.40 The presence of 
chelating agents modulates the interaction between JR2EC and Zn2+, giving profound effects 
on the LSPR band of the GNP. The system thus represents a sensitive detection system for 
Zn2+ binding species, which are prevalent in nature. 
Gupta et al.41 reported a one-step kinase assay involving two different functionalized 20 nm 
GNPs. The GNPs were modified with either the peptide Ac-IYGEFKKKC, which is a Src-
kinase enzyme substrate or with anti-phosphotyrosine antibodies (Figure 9). When nanomolar 
concentrations of v-Src kinase and ATP were incubated with both types of GNPs, they 
changed from well-dispersed to aggregated. Since both kinase and ATP have to be added to 
the gold solution to cause the change, this method can be applied to specific drug screening if 
it involves inhibition of kinase activity.  
  
Figure 9. A peptide-GNP aggregation immunoassay for kinase detection.41 Reproduced with 
permission © Wiley-VCH, 2010. 
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Multivalent labelled fluorescence-quenched GNP probes for the detection of proteolytic 
activity in vivo have also been developed.42 A near-infrared fluorophore (Quasar 670) and 
quencher (BHQ-2) were covalently attached to protease substrates bearing a Cys at the C-
terminus for conjugation to GNPs. Protease activity cleaved the peptide substrate, releasing 
the dye from the GNP surface giving quantifiable fluorescence. The self-assembled GNP 
probes were found to exhibit high image contrast in a tumour phantom model, and to have a 
long circulation time (t1/2>4 h) in vivo. This study shows that multivalent labelled GNP 
probes have great potential application in detection and therapeutic delivery.  
Recently, GNPs have been developed as colourimetric immunosensors. Yuan et al.43 
developed glutathione (GSH)-functionalized GNPs for detecting neurofenin3 (ngn3), which 
is essential in the development of islet cells.  Previous studies had shown that mice that 
cannot produce ngn 3 fail to generate pancreatic endocrine cells and subsequently die from 
diabetes.44, 45  Based on this work, the development of new methods to detect ngn3 is 
potentially very useful. Anti-ngn3 antibody was bound to GSH-GNPs through electrostatic 
interactions to form GNP-Ab. In the presence of either ngn3 or NaCl, the UV-vis absorbance 
was similar to that of GNP-Ab alone, however when both ngn3 and NaCl were added, a 
broad new band appeared at high wavelength corresponding to GNP aggregation (Figure 10). 
The positively charged ngn3 and negatively charged anti-ngn3 combine to neutralize the 
surface charge, and the neutral nanoparticles aggregate in salt solution. This is the first 
example of a label-free colourimetric assay to detect ngn3 easily by optical absorption spectra.  
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Figure 10. Antibody-functionalised GNPs for detecting neurofenin3 (ngn3). (A) Absorption 
spectra of Anti-ngn3-GNPs in the presence of no additive, ngn3, NaCl and ngn3+NaCl; (B–E) 
corresponding TEM images plus photos ((B): no additive; (C): +ngn3; (D): +NaCl; (E): 
+ngn3+NaCl).43 Reproduced with permission © Elsevier, 2011. 
 
In 2012, Saxena et al.46 discovered a novel approach to detect bluetongue virus (BTV)-
specific antibodies based on multiple antigenic peptide (MAP)-functionalized GNPs. In this 
work, an antigenic peptide was designed based on the region of the BTV structural protein 
VP7. This protein was chosen as it shows high sequence homology amongst the serotypes. 
Gold nanoparticles were decorated with antigenic peptides in a format with a cysteine core 
and four arms linked through Di-Fmoc-Lys, to amplify the sensitivity. When GNPs labeled 
with MAP met the specific BTV antibodies, they became aggregated resulting in a colour 
change from pink to violet. This novel approch using MAP fuctionalized GNPs has the 
advantage of minimizing the risk of infectious organisms and highly specific targeting to 
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BTV antibodies at the same time. A peptide-GNP system for detection of botulinum 
neurotoxin (BoNT) was also developed.47 GNPs were surface functionalised with a peptide 
cleavage site for Botulinum A light chain (BoLcA), bearing a C-terminal biotin moiety. In the 
presence of streptavidin-Alexa488 complex, energy transfer between the dye and the GNP 
resulted in fluorescence quenching. Addition of BoLcA cleaved the peptide, releasing the 
Alexa conjugate from the nanoparticle surface and swtiching on fluorescence. BoClA could 
be detected at concentrations as low as 1pM using this approach. 
A GNP system that could detect interaction between the estrogen receptor alpha subtype 
(hERα) and agonist ligands was reported.48 The GNPs were functionalized with peptides that 
contained a section of SRC-1, which is a co-activator for a nuclear receptor. Aggregation of 
GNPs in solution only occurs in the presence of an agonist ligand, as confirmed by a red shift 
of the SPR absorption band and a colour change from red to blue (Figure 11). This assay 
gives a better understanding of ligand agonist/antagonist activity compared to former assays 
and is applicable for screening in drug discovery. 
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Figure 11. SRC-1 peptide-functionalised GNPs for detection of the interaction between 
estrogen receptors and agonist ligands.48 Image re-used under Creative Commons Attribution 
Licence (CC-BY 3.0).  
 
Detection of proteins by double-recognition peptide-aptamer-functionalized GNPs has been 
described recently.49 The binding sequences of proteins p53 and p14, which form a ternary 
complex with oncoprotein Mdm2, were attached separately to the surface of GNPs. When  
Mdm2 was added to mixed solutions of the two GNPs, a large shift in LSPR and an 
associated colour change from red to purple was observed. A remarkably low detection limit 
of 20nM was demonstrated, with a linear response in the range 30-50nm. No aggregation was 
observed in the presence of BSA (even at physiological concentration), or if only one of the 
peptide aptamer-GNPs was present. A GNP protein-detection assay employing a smartphone 
as detector has also been described recently.50 Protein-detecting gold nanorods have been 
incorporated into a paper-based biodiagnostic device.51 A peptide that binds human troponin 
1, a cardiac biomarker, was identified by phage display and attached to the surface of the gold 
nanorods via a C-terminal Cys. The peptide-GNPs were absorbed into paper to create a 
bioplasmonic device; the detection limit of the target protein troponin 1 was 35.3 pg/ml, one 
order of magnitue lower than an analogous Ab-GNP bioplasmonic device. Furthermore, the 
peptide-GNP system showed greater stability and better sensitivity in physiological media 
than the antibody-modified GNPs. 
A  dot-blot GNP-based immunoassay for detecting β-amyloid peptide (Aβ1-42) was created by 
Wang and co-workers.52 The C-terminal antibody of Aβ1-42 was immobilized on a 
nitrocellulose membrane. On top of this, biotin- and N-terminal Aβ1-42 antibody- 
cofunctionalized GNPs (Ab16-GNP) plus streptavidin-functionalized GNPs (SA-GNP) were 
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added. These nanoparticles bind together through biotin-streptavidin interaction, amplifying 
the detection signal. In the presence of Aβ1-42, a does-dependent positive dot-blot 
immunoassay was clearly observed on the fixed nitrocellulose membrane (Figure 12). This 
detection method is easy and efficient for complex biosamples and can detect Aβ1-42 down to 
50 pg mL-1 in solution.  
 
Figure 12. A GNP-based dot-blot immunoassay for detecting the β-amyloid petide Aβ1-42.52 
Reproduced with permission © Royal Society of Chemistry, 2012. 
 
In 2014, Chandrawati et al.53 demonstrated a label-free detection method for blood 
coagulation factor XIII activity based on the optical and electronic properties of GNPs. Factor 
XIII is active in the presence of thrombin and Ca2+ and it catalyses the formation of an amide 
bond between the side chains of the amino acid residues Gln and Lys. GNPs were 
functionalized separately with two different peptides, CALNNGQG and CALNNGKG. If 
factor XIII is present, the Gln-Lys bond forms an intermolecular crosslink between the two 
types of GNPs and aggregation occurs. A red shift of the surface plasmon resonance (SPR) 
absorption band confirmed the aggregation and a solution colour change from red to blue was 
observed (Figure 13). A linear relationship between the concentration of Factor XIII and the 
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difference of the maximum absorbance peak (∆λmax) was observed and the detection limit 
was down to 0.01U mL-1. This provides a label-free and very sensitive approach to detect the 
activity of Factor XIII.  
 
 
Figure 13. Label-free detection of blood coagulation Factor XIII activity by the controlled 
assembly of peptide-GNPs in the presence of thrombin and Ca2+.53 Reproduced with 
permission © Royal Society of Chemistry, 2014. 
 
4.2 Targeted Drug Delivery and Cellular Uptake  
In recent years, peptides have been used in a variety of biomedical applications, including as 
targeting probes, drug carriers and synthetic vaccines, because of their small size, 
biocompatibility, cell-penetrating ability, easy chemical synthesis and modification.5, 6 Chan 
et al.54 found that GNPs with diameters between 20-60 nm have the highest uptake in HeLa 
cells. Also, it was found that some peptides, known as cell-penetrating peptides (CPPs), can 
be uptaken specifically by certain cell organelles. They can be conjugated to an anti-cancer 
drug and used as a drug carrier. Functionalization of gold nanoparticles (GNPs) with a cell-
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penetrating peptide has been performed with the aim of improving the efficiency of living 
cell uptake.  
In 2005, Fuente and Berry55 attached the HIV-derived CPP Tat (GRKKRRQRRR) to GNPs 
in order to develop a system that was able to target the cell nucleus.. The GNPs were firstly 
synthesized by reduction of AuCl4
- solution in the presence of tiopronin which has a thiol end 
group. Secondly, Au@tiopronin acid groups and Tat peptide amine groups were conjugated 
via EDC/NHS coupling to give Au@Tat nanoparticles. This strategy has been also used to 
develop water-soluble and biocompatible fluorescent quantum dots which can translocate to 
the nucleus.56 Human fibroblast cells (HTERT-BJ1) were used to test the biocompatibility of 
Au@tiopronin and Au@Tat and cell uptake was investigated by TEM. These results indicate 
that this Tat peptide can transfer the nanoparticles into the cell nucleus. Without the peptide 
functionalization, Au@tiopronin nanoparticles could not penetrate the cell membrane and 
target the cell nucleus, proving the cell-penetrating ability of Tat peptide. This work has 
many potential applications in cancer therapy, for example as a carrier for drug delivery. 
However, the ratio of Tat/tiopronin on the surface is about 1:50 which is low and makes it 
hard to quantify Tat loading. In related work, Tat-GNPs were used to probe the spatio-
temporal uptake of nanoparticles by HeLa cells, using dual wavelength view darkfield 
microscopy.57 Uptake was shown to be by energy dependent endocytosis; interestingly, Tat-
GNPs were passed on to daughter cells by mitosis. Tat has also been conjugated to gold 
nanostars to create ultra-bright imaging agents for tracking mesenchymal stem cells (MSCs) 
after implantation in mice.58 These peptide-gold nanostar clusters gave a stronger and slower 
decaying intracellular signal than the commercial cell tracking agent Q-Tracker (a peptide-
conjugated quantum dot). 
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In 2008, Sun et al.59 utilised a CPP-modified CALNN derivative (CALNNR8) to prepare 
GNPs that could target intracellular components. In this study, GNPs of three different sizes 
(13nm, 30nm, 60nm) were synthesized by the Frens-Turkevich method.3, 4 The peptide-
capped GNPs were then prepared by a one-step gold-thiol reaction. The ratio of the 
CALNNR8 to CALNN on the surface of the GNPs was determined to be 1:9 respectively. 
After incubation with HeLa cells, it was found that the peptide-GNPs had translocated into 
the cell nucleus. However, if the system was modified to only contain CALNNR8, the GNP 
complex did not reach the nucleus and it was found to remain in the cytoplasm. It was also 
found that the size of the gold particles can affect cellular internalization. Larger GNPs (60 
nm) were internalized to a lesser extent by HeLa cells compared to smaller (13 nm and 30 nm) 
nanoparticles. The mechanism behind this is still unclear and needs to be investigated further. 
Penetratin, another example of a CPP, was employed as a ligand to enhance passage of gold 
nanostars across the blood-brain barrier (BBB) for photothermal disruption of -amyloid 
fibrillation.60 A derivative of maurocalcine (MCa), an alternative CPP, enabled enhanced 
uptake in certain cancer cell lines when attached to GNPs surface, but not in others.61 
Interestingly, the MCa derivative, unlike most CPPs, is charge neutral, indicating that its cell-
penetrating mechanism may not be electrostatic. 
A GNP system for targeting tumour vasculature has been reported by Shukla et al.62. Arg-
Gly-Asp (RGD) peptide-functionalized dendrimer-entrapped gold nanoparticles (AuDENPs) 
which can be taken up by αVβ3 integrin-expressing cell lines were prepared. The αVβ3 integrin 
is an important marker of the neovasculature and is normally found during tumour 
angiogenesis; without it, tumours cannot grow beyond 1-2 mm in size.63 AuDENPs with a  
mean diameter of 3.0 nm were synthesized.64 Human dermal microvessel endothelial cells 
(HDMEC) and human vascular endothelial cells (HUVEC) were used to examine the binding 
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ability of Au DENPs and confocal microscope results confirmed the internalization of gold in 
the integrin-expressing cells. Given that the RGD peptide has a high affinity to αVβ3 integrin, 
the RGD-functionalized GNPs can be used as a drug carrier system to delivery anti-cancer 
drugs or pro-apoptotic peptides.65 However, the interaction between linear RGD peptides and 
αVβ3 integrin is often weak and the utility of individual ligands is limited for efficient tumour 
targeting. Arosio et al.66 improved this approach by using cyclic RGD derivatives to 
functionalise GNPs. A short poly(ethylene glycol) (PEG) was used as a spacer to combine the 
cRGD and the GNPs, and to enhance the stability of the nanoparticle system. Experimental 
results with PC-3 prostate cancer cells showed that cRGD-conjugated GNPs had enhanced 
affinity for αVβ3 integrin compared with the unconjugated system.  
Another cyclic RGD (RGDfK) peptide-functionalized GNP system has been reported in 
which Multiphoton-Absorption-Induced Luminescence (MAIL) was used to monitor GNP 
uptake into cells.67 HUVECs were incubated with cyclic RGDfK- and linear RGD 
(GRGDSP)-functionalized GNPs. MAIL showed that the number of GNP-RGDfK conjugates 
targeted to HUVECs was an order of magnitude higher than GNP-GRGDSP. MAIL imaging 
also demonstrated that the mechanism of uptake of the GNP-RGDfK conjugate into cells 
involves αVβ3 integrin-mediated endocytosis which is a specific binding event. Ghosh et al.68 
synthesized GNPs coated with a short peptide that can promote intracellular delivery of β-
galactosidase (β-gal), which is a 465 kDa membrane-impermeable protein (Figure 14). The 
peptide ligand was attached to the end of a spacer containing a hydrophobic domain adjacent 
to the nanoparticle surface and a short, passivating, oligoethyleneglycol sequence. 
Fiammengo’s group69 similarly prepared peptide-functionalised GNPs where a toxic N-
methyl-D-aspartate (NMDA) receptor targeting peptide, conantokin-G (conG), was tethered 
at the end of an alkyl-PEG spacer unit in a mixed monolayer. The peptides could be 
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conjugated selectively to the end of the alkyl-PEG spacer and thus gave maximum receptor 
binding, while use of a heterobifunctional PEG without an alkyl sequence also resulted in 
some direct peptide attachment to the gold surface. 
 
Figure 14. Short peptide-coated GNPs for intracellular delivery of β-galactosidase (β-gal): (a) 
Schematic showing intracellular delivery mechanism; (b) structure and properties of the GNP, 
β-gal and the peptide ligand.68 Reprinted with permission from P. Ghosh, X. Yang, R. Arvizo, 
Z.-J. Zhu, S. S. Agasti, Z. Mo and V. M. Rotello, J. Am. Chem. Soc., 2010, 132, 2642-2645. 
Copyright 2010 American Chemical Society. 
 
Amphiphilic peptide-functionalized GNPs which can encapsulate a cargo and release it 
following a biostimulus have been described.70 An amphiphilic peptide containing a 
hydrophobic core of repeating units (PPG)n (n=3, 5, 8 or 10) and a hydrophilic exterior 
sequence of four aspartic acids (D) was used. The hydrophobic dye BODIPY was 
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encapsulated into the particles as a drug model; the GNP-(PPG)5  showed the highest loading 
capacity due to the largest hydrodynamic radius. Based on this, a thrombin cleavable peptide 
DDDD(PPG)2LVPRGS(PPG)3GC ((PPG)5’) was designed. In the presence of thrombin, Arg-
Gly (R-G) amide bonds are cleaved. A short peptide DDNNLAC and (PPG)5’ were used at a 
ratio of 1:1 to form a mixed monolayer on the gold nanoparticle surface and then the hybrid 
particles were used to encapsulate BODIPY. Without thrombin, BODIPY was released 
slowly while in the presence of thrombin it was released rapidly. This novel stimulus-release 
drug delivery model has the potential to be applied to cancer cells, while the use of other 
proteases to replace thrombin can diversify the field of application. 
Yang et al.71 investigated the effect of surface chemistry of different peptide-functionalised 
GNPs on their interaction with cells. The peptides contained a gold-binding cysteine, a 
hydrophobic spacer of four alanine residues and end groups with different charge status, such 
as arginine (P1), lysine (P5), glutamic acid (P2), serine (P3) and tryptophan (P4). Stability 
experiments showed that only the negatively charged glutamic acid-ended peptides prevented 
GNPs from aggregating. By changing 5-10% of the end group amino acid residues, various 
P2-P3 and P2-P4 mixed-functionalized GNPs were synthesized and their cellular uptake 
properties were studied. It was shown that mixed peptide 95P2P4 (95% P2 and 5% P4) 
functionalized-GNPs had enhanced cellular uptake properties. This enhancement was thought 
to be due to the ability to interact with cellular membranes afforded by the aromatic amino 
acid tryptophan (P4). Terminal amino acids were similarly shown to affect the toxicity of 
glutathione-modified GNPs.72 Bartczak et al.73 studied the cellular uptake properties and 
exocytosis behaviour of two different types of peptide-GNPs in human endothelial cells 
(HUVECs). The first peptide KATWLPPR interacts strongly with endothelial-expressed 
receptor Neuropilin 1 (NRP-1) as an inhibitor, while the second peptide KPRQPSLP does not 
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interact with surface-bound receptors. Both peptides were attached to oligoethyleneglycol 
(OEG) modified GNPs through EDC/NHS chemical conjugation. Endothelial cell 
experiments showed that both peptide-GNPs can be taken up in greater numbers compared to 
bare GNPs. However, NRP-1 non-binding GNPs are retained by cells while the inhibitor-
GNPs are progressively exocytosed. 
 
4.3 Delivery of Anti-cancer peptides 
In vitro experiments have shown that some peptides have the ability to kill cancer cells and 
inhibit tumour growth. These anti-cancer peptides can be used as therapeutics and a range of 
systems for their targeted/controlled delivery have been studied. One such approach is the 
functionalization of GNPs with a targeting peptide, which has been used to deliver anti-
cancer peptides specifically to tumour cells. 
In 2010, Chanda et al.74 conjugated analogues of the peptide bombesin (BN) to GNPs. 
Bombesin is a gastrin-releasing peptide (GRP) that can specifically target cancer cell receptor 
sites. It is known that BN peptides have a high affinity for GRP receptors which are 
overexpressed in breast, prostate and lung carcinomas. Human prostate tumour PC-3 cells 
were used to evaluate the GRP receptor binding affinity of BN-functionalized GNPs. The 
higher the degree of BN peptide on the GNP surface, the higher was the cell binding affinity, 
as shown by lower IC50 values. A multi-functionalized GNP system that contains both BN 
and a therapeutic peptide has also been developed.75 RAF peptide inhibits in vivo the kinase 
Rb-Raf-1 and thus prevents cell proliferation. GNPs of 20 nm diameter were synthesized by 
the sodium citrate reduction method,4 and these were then conjugated with BN and RAF. The 
multi-functionalized GNP system was found to penetrate HeLa cells which overexpress GPRr, 
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while it was not taken up by SHSH-5Y cells which do not overexpress the same receptor 
(Figure 15). The mechanism of internalization into HeLa cells is still under investigation.  
 
Figure 15. Multifunctionalization of gold nanoparticles with a targeting peptide (bombesin; 
BN) and an antitumoral peptide (RAF).75 Reprinted with permission from L. Hosta-Rigau, I. 
Olmedo, J. Arbiol, L. J. Cruz, M. J. Kogan and F. Albericio, Bioconjug. Chem., 2010, 21, 
1070-1078. Copyright 2010 American Chemical Society. 
 
Further work involving BN as a cancer-targeting ligand for GNPs has revealed stark 
differences between in vitro and in vivo behaviour.76 67Ga-radiolabelled GNPs either with or 
without a surface-bound BN derivative were prepared and their uptake into GRPr-positive 
human pancreatic cancer cells was investigated. Remarkably raid and efficient uptake (25% 
after 15 min) of GNPs bearing a BN derivative was observed. Mechanistic studies revealed 
that uptake most likely occurs via active pathways (phagocytosis and/or endocytosis). 
However, follow-up experiments in mice indicated high uptake of BN-GNPs into organs 
including the liver, spleen and lungs with low uptake (3.3-3.7% after 24h) in tumour tissue. 
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Furthermore, GRPr blocking experiments had no effect on uptake, indicating that GNPs are 
being uptaken in tumours by a passive (EPR) mechanism. These results highlight the 
difficulties of translating in vitro nanoparticle cancer targeting approaches to success in 
vivo.77 
In 2012, Kumar et al.78 developed novel small GNPs (2 nm) functionalized with both a 
therapeutic peptide (p12) and a targeting peptide (CRGDK). The targeting peptide is known 
to bind selectively to Nrp-1 receptors which are overexpressed in many tumour cells.  
Through receptor-mediated internalization, targeting peptide-functionalized GNPs can 
translocate into the cell and the nucleus. At the same time, the therapeutic peptide p12 binds 
to MDM2 and MDMX proteins leading to the expression of tumour suppressive protein p53, 
which limits the expression of tumour genes thus causing cell apoptosis.79 The same GNP 
synthesis method as is shown in Figure 1 was used, giving small Au@tiopronin to which 
were added peptide p12, CRGDK or both peptides together. The targeting peptide was shown 
to enhance the cellular uptake of the gold nanoparticles with the therapeutic peptide payload. 
A multifunctional GNP system with the same targeting peptide (CRGDK) and a platinum (IV) 
drug for prostate cancer treatment was also reported.80 The anti-cancer targeting nanocarrier 
had improved efficiency of intracellular uptake compared to non-targeting analogues and 
enhanced cytotoxicity (8.25 times more cytotoxic than non-targeting Pt(IV)-modified GNPs). 
Ma et al.81 and Chen et al.82 have reported two similar systems which use a pro-apoptotic 
peptide (KLAKLAK)2 to functionalize GNPs for enhanced cancer treatment (Figure 16). The 
cytotoxic KLA peptide disrupts the mitochondrial membrane, resulting in release of 
cytochromes and induction of apoptosis. In Ma’s system, GNPs was firstly stabilized with a 
biotinylated CALNN-based peptide (biotin-NNLACCALNN-COOH), then a tetrameric 
streptavidin layer, and lastly a biotinylated KLA peptide. Chen’s group used only KLA 
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peptide (referred to as pro-apoptotic peptide, or PAP) to functionalize gold nanoparticles. In 
both systems, the KLA peptide-functionalized GNPs displayed greatly enhanced activity 
compared to free KLA peptide. Derivatives of KLA peptides with better cell penetrating 
ability were identified using prediction software, the best candidate being WKRAKLAK.83 
This was conjugated to GNPs of different size and shapes (spheres and rods) via a lipoic acid 
spacer. Strong influence of GNP size and shape on cancer cell uptake and cytotoxicity were 
observed. For example, smaller nanospheres were uptaken more efficiently and were more 
cytotoxic, while nanorods were more hemolytically active than nanospheres. These results 
demonstrate the importance of GNP size and shape on activity. 
 
 
Figure 16. GNP systems for the delivery of anti-cancer peptide KLA: A) a gold nanoparticle core 
with multi-layered presentation of KLA peptide.81 B) GNPs directly functionalized with the pro-
apoptotic peptide (PAP) KLA.82 Reproduced with permission © Royal Society of Chemistry, 
2013. 
 
4.4 Oligonucleotide Delivery and Regulation of Gene Expression 
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Cationic macromolecules have the ability to bind and condense oligonucleotides and thus 
have been the result of intense investigation as non-viral vectors for gene and RNA delivery. 
In particular, poly(ethyleneimine) (PEI), PEGylated poly(L-lysine) (PEG-PLL), PAMAM 
dendrimers and a cationic lipid known as Lipofectamine® have been the most commonly 
studied oligonucleotide vectors. Gold nanoparticles have been employed in some studies as 
non-toxic delivery platforms for cationic vectors, in conjugation with cell-penetrating 
peptides or other targeting moieties for enhancing transfection of oligonucleotides. 
Franzen and Liu employed streptavidin-conjugated gold nanoparticles as a multifunctional 
platform for the delivery of a biotinylated antisense oligonucleotide, together with various 
biotinylated targeting peptides84. It was found that targeting peptide-conjugated GNPs 
displayed enhanced antisense activity roughly two-fold relative to Lipofectamine® (LF) 
control, however only in the presence of free LF. The presentation of the oligonucleotide on 
the GNP surface may expose it to harsh conditions once inside the endosome, leading to its 
degradation. The presence of free LF was suggested to ameliorate this, possibly by allowing 
the oligonucleotide to escape the endosome and access the nucleus. Kataoka and coworkers 
employed cyclic-RGD (cRGD) as a targeting ligand for GNP-mediated delivery of siRNA to 
silence an HPV-derived oncogene85. A cRGD-PEG-PLL-lipoic acid construct was complexed 
with the siRNA sequence then the complex was immobilised on citrate-GNPs. The presence 
of cRGD both enhanced gene silencing in vitro and decreased tumour size in an in vivo 
(mouse) model. Cationic polypeptide-conjugated GNPs were prepared in a single-step 
process whereby the polypeptide acts both to reduce HAuCl4 and stabilise the resulting 
GNPs86. Poly(L-lysine) (PLL)-containing polypeptides were able to bind a GFP plasmid 
DNA sequence and high levels of transfection were demonstrated in vitro after 10 days. At 
earlier times, however, transfection efficiency was lower than analogous systems without the 
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GNP platform. This was attributed to the observed significant GNP clustering at earlier time 
points, which was also accompanied by higher cytotoxicity of GNP-polypeptide constructs. 
Cell-penetrating peptides (CPPs) have been employed to enhance uptake of GNP non-viral 
gene transfer vectors. A novel zwitterionic cell penetrating pentapeptide was conjugated to 
GNPs that also carried a linearised plasmid encoding for a brain-derived neurotrophic factor 
(BDNF)/mCherry fusion protein, for transfection of mesenchymal stem cells (MSCs)87. 
Transfection efficiency as measured by mCherry expression was massively enhanced 
compared to LF control. MSC transfection was also assisted by an antimicrobial CPP from 
lactoferrin88.  This CPP, known as PEP, was co-immobilised with PEI onto GNPs and used to 
deliver a luciferase reporter gene to MSCs. High transfection efficiency both in vitro and in 
vivo (the latter using pDNA-VEGF as a reporter) was observed in the presence of PEP-GNPs; 
in vitro transfection was around 100 times higher than that of PEI control.  Furthermore, high 
antimicrobial activity of the PEP-GNP conjugates was demonstrated in vitro and in vivo. 
Parang et al. employed the cyclic decapeptide (WR)5 both to reduce Au
3+ and cap in-situ 
formed GNPs89. These were shown to deliver a non-targeting siRNA sequence to HeLa cells 
with high levels of uptake. 
In addition to the delivery of oligonucleotides, peptide-GNPs have also been used as artificial 
transcription factors (TFs) to alter gene expression. Lee et al. conjugated separately to GNPs 
peptide sequences representing the three essential domains of natural TFs, namely a nuclear 
localisation signal, a DNA binding domain and an activation domain90. The resulting 
construct, named NanoScript, was co-transfected with an alkaline phosphatase (ALP) reporter 
plasmid into HeLa cells. ALP expression was found to be dose-dependent on NanoScript 
concentration, and was enhanced 15-fold relative to control only when all three TF domain 
peptides were present. 
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5. Conclusions and Outlook 
In conclusion, gold nanoparticles (GNPs) can be functionalized by peptides through ligand 
exchange, chemical reduction and chemical conjugation methods. The attached peptides can 
increase the stability and biocompatibility of the GNPs. The wide range of synthetic methods 
available provides an opportunity to conjugate almost any biofunctional peptide to the surface 
of GNPs. In this review, the use of peptide-GNPs as sensitive biosensors, drug carriers, anti-
cancer therapeutics and gene delivery vectors has been discussed. The rapidly increasing 
number of papers published in this area clearly shows the potential of peptide-GNPs in 
nanomedicine. There are however a number of issues that still need to be resolved, including: 
developing methods for precisely controlled functionalization; elucidation of mechanisms of 
molecular recognition on the surface of GNPs; determination of the mechanism of 
internalization of peptide-GNPs into cells.  The long-term stability and toxicity of GNP-
peptide systems also must be studied in more detail. Recent in vivo studies involving peptide-
GNPs have not revealed any significant toxicity. Biodistribution studies in mice of CPP-
functionalised GNPs indicated nanoparticle concentration in the liver and spleen but without 
any noticeable tissue damage91.  Similarly, pentapeptide-GNPs (CALNN and others) 
concentrated in the liver following intravenous injection in rats, again without any signs of 
toxicity92. Other in vivo studies conducted using cyclic-RGD-conjugated nanogold tripods93, 
RGD-gold nanorods94, VEGF-receptor binding peptide-95 and adipose homing peptide-
functionalised GNPs96 similarly did not reveal any evidence of toxicity or other adverse 
effects, although it should be pointed out that all these studies are relatively short-term. An in 
vivo study in mice of unfunctionalised GNPs indicated significant toxicity of nanoparticles in 
the size range 8-37nm however, interestingly, conjugation of immunogenic peptides to the 
37 
 
GNPs reduced toxicity significantly97. Further studies are required to investigate more fully 
the in vivo effect of peptide-functionalised GNPs. 
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